Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TNON
TNON logo

TNON Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.326
Open
0.326
VWAP
0.30
Vol
71.66M
Mkt Cap
5.66M
Low
0.272
Amount
21.27M
EV/EBITDA(TTM)
--
Total Shares
17.38M
EV
7.03M
EV/OCF(TTM)
--
P/S(TTM)
0.59
Tenon Medical, Inc. is a medical device company. The Company has developed the Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Its trademarks include Catamaran, PiSIF, CAT PiSIF, ETAD, CAT SIJ Fusion System, SImmetry, MAINSAIL, SImmetry+, Catamaran Transfixation Fusion Device, Catamaran Transfixation Fusion System, and others. The Catamaran SI Joint Fusion System offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant.
Show More

Events Timeline

(ET)
2026-07-02
08:30:00
Tenon Medical Receives FDA Clearance for Catamaran SI Joint Fusion System
select
2026-06-30 (ET)
2026-06-30
09:30:00
Tenon Medical Prices Public Offering for Approximately $4.2M
select
2026-02-18 (ET)
2026-02-18
08:50:00
Tenon Medical Expands U.S. Intellectual Property Portfolio
select
2026-02-05 (ET)
2026-02-05
09:00:00
Reaffirms FY25 Revenue View at $3.91M-$3.94M
select
2026-01-28 (ET)
2026-01-28
08:40:00
Tenon Medical Expects 2025 Revenue of $3.91 Million
select
2025-12-10 (ET)
2025-12-10
06:10:00
Tenon Medical Files to Sell 5.43M Shares of Common Stock
select
2025-12-04 (ET)
2025-12-04
08:40:00
Tenon Medical Completes First Clinical Procedures with SImmetry+ SI Joint Fusion System
select

News

Newsfilter
8.5
07-02Newsfilter
Tenon Receives FDA Clearance for Catamaran SI Joint Fusion System
  • FDA Clearance Update: Tenon Medical has received FDA 510(k) clearance for its updated Catamaran® SI Joint Fusion System, which includes various instrument upgrades and reclassification of certain disposable instruments to reusable status, expected to significantly lower per-procedure costs, thereby enhancing the company's gross margins and cash flow.
  • Economic Benefit Enhancement: By transitioning disposable instruments to reusable ones, Tenon anticipates reduced capital expenditures and logistical costs, a strategic improvement that will directly drive the company's financial health and strengthen its competitive position in the medical device market.
  • Market Adoption Progress: Since the national launch of the Catamaran system in October 2022, over 1,500 Catamaran fixation devices have been implanted in patients across the United States, indicating strong market demand for the product in treating sacroiliac joint disruptions and degenerative sacroiliitis.
  • Commitment to Continuous Innovation: Tenon's CEO Steven M. Foster stated that this clearance reflects the company's ongoing commitment to refining the Catamaran system, aimed at providing better treatment experiences for physicians and patients while laying the foundation for sustainable growth.
PRnewswire
8.5
07-01PRnewswire
Tenon Medical Completes $4.2 Million Public Offering
  • Funding Amount: Tenon Medical successfully completed a public offering raising $4.2 million, issuing 11,052,631 shares of common stock and 13,263,159 common stock purchase warrants, demonstrating the company's capital market capabilities.
  • Use of Proceeds: The funds will be allocated for repaying convertible notes, expanding the commercial footprint of its product portfolio, training clinicians, and hiring additional sales representatives, aiming to enhance market competitiveness and product coverage.
  • Warrant Details: Each common stock warrant can be exercised at an exercise price of $0.38 per share and is immediately exercisable, which increases investor participation and market liquidity.
  • Legal Compliance: The offering is conducted under SEC registration statements, ensuring compliance and laying a foundation for future fundraising activities, reflecting the company's commitment to transparency and regulatory adherence.
PRnewswire
8.5
06-30PRnewswire
Tenon Medical Prices Public Offering for $4.2 Million
  • Offering Size and Price: Tenon Medical announced a public offering of up to 11,052,631 shares at a price of $0.38 per share, aiming for approximately $4.2 million in gross proceeds, reflecting the company's active engagement in capital markets and financing capabilities.
  • Diverse Use of Proceeds: The funds raised will be allocated for repaying convertible notes, expanding the commercial footprint of its product portfolio, training clinicians, and hiring additional sales representatives, which aims to enhance market competitiveness and customer service capabilities.
  • Legal and Underwriting Support: WallachBeth Capital LLC serves as the sole placement agent for the offering, while Sichenzia Ross Ference Carmel LLP and Sheppard, Mullin, Richter & Hampton LLP provide legal counsel to the company and the placement agent, ensuring compliance and smooth execution of the offering process.
  • Future Outlook and Risks: Tenon Medical indicated that future revenues and developments will be influenced by various factors; while the current financing activity provides necessary funding, attention must be paid to market changes and potential risks.
seekingalpha
8.5
06-30seekingalpha
Tenon Medical Prices $4.2M Public Offering
  • Offering Pricing: Tenon Medical announced a public offering priced at $0.38 per share for up to 11.05 million common shares and accompanying warrants, aiming to raise $4.2 million before placement agent fees and other expenses, indicating the company's ability to access capital markets.
  • Clear Use of Proceeds: The funds will be utilized to partially repay outstanding convertible notes, expand commercial operations, support R&D, increase inventory capacity, and fund working capital and other general corporate purposes, reflecting strategic financial management.
  • Negative Market Reaction: Despite successfully pricing the offering, the company's shares fell by 12.79%, indicating a negative market response to the financing plan, which could impact investor confidence and future fundraising capabilities.
  • Future Development Plans: Tenon Medical plans to fully launch SImmetry+ in the second half of 2026 and targets Alpha for a third approach in Q4 2026, demonstrating the company's proactive strategy in product development and market expansion.
Yahoo Finance
8.5
06-30Yahoo Finance
Tenon Medical Prices $4.2 Million Public Offering
  • Offering Size: Tenon Medical has priced a public offering of up to 11,052,631 shares at $0.38 per share, aiming for approximately $4.2 million in gross proceeds, reflecting the company's ability to access capital markets effectively.
  • Use of Proceeds: The net proceeds from this offering will be allocated towards repaying outstanding convertible notes, expanding the commercial footprint of its product portfolio, training clinicians, and hiring additional sales representatives, which is expected to enhance market competitiveness and customer service capabilities.
  • Legal Compliance: WallachBeth Capital LLC acts as the sole placement agent for this offering, ensuring compliance and market trust, while also indicating the company's diligence in legal matters.
  • Investor Information: Tenon Medical will conduct this offering under SEC registration statements, ensuring transparency and providing necessary legal protections for investors, thereby boosting market confidence in its future growth prospects.
NASDAQ.COM
8.5
06-23NASDAQ.COM
Tenon Files S-1, Stock Surges 77.57%
  • Tenon Stock Offering: Tenon Medical Inc. (TNON) filed a Form S-1 to offer up to 1.81 million shares and 6.98 million warrants at a public offering price of $0.6021 per unit, with potential proceeds aimed at bolstering future growth, especially if a reverse stock split occurs, increasing warrant exercise shares to 8.72 million.
  • Azitra's Strategic Shift: Azitra Inc. (AZTR) outlined its 2026 roadmap in a shareholder letter, focusing on the ATR-COSF program for the cosmetic market, with clinical studies expected to start by late 2026, positioning the company for potential commercialization by 2027, enhancing its competitive edge in precision dermatology.
  • Nuvectis Licensing Deal: Nuvectis Pharma Inc. (NVCT) announced a strategic licensing agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200, which could open new market opportunities in treating complement-mediated diseases and BRAF mutations.
  • REGENXBIO's FDA Alignment: REGENXBIO Inc. (RGNX) has aligned with the FDA for the resubmission of its Biologics License Application for NAVSUNLI, with the FDA acknowledging existing clinical data sufficiency for accelerated approval, anticipating resubmission in Q3 2026, which could significantly impact the company's market position in gene therapy for Hunter syndrome.
Wall Street analysts forecast TNON stock price to rise
2 Analyst Rating
Wall Street analysts forecast TNON stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
2.50
Averages
2.75
High
3.00
Current: 0.000
sliders
Low
2.50
Averages
2.75
High
3.00
Alliance Global
Scott Henry
Buy
downgrade
AI Analysis
2026-05-13
Reason
Alliance Global
Scott Henry
Price Target
AI Analysis
2026-05-13
downgrade
Buy
Reason
Alliance Global analyst Scott Henry lowered the firm's price target on Tenon Medical to $2.25 from $2.50 and keeps a Buy rating on the shares. The firm notes Tenon Medical reported Q1 earnings that were within the range of its expectations. Alliance Global points out that Q1 revenue was slightly below its estimate, the key focus will be on the ongoing launch of SImmetry+ and that the cash balance suggests a runway into Q3 2026.
Alliance Global
Buy
downgrade
2025-11-14
Reason
Alliance Global
Price Target
2025-11-14
downgrade
Buy
Reason
Alliance Global lowered the firm's price target on Tenon Medical to $2.50 from $2.75 and keeps a Buy rating on the shares. The firm's revised target reflects lower forecasts following the company's Q3 report.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TNON
Unlock Now

Valuation Metrics

The current forward P/E ratio for Tenon Medical Inc (TNON.O) is 0.00, compared to its 5-year average forward P/E of -3.02. For a more detailed relative valuation and DCF analysis to assess Tenon Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.02
Current PE
0.00
Overvalued PE
12.73
Undervalued PE
-18.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.03
Current EV/EBITDA
-0.17
Overvalued EV/EBITDA
0.06
Undervalued EV/EBITDA
-0.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.07
Current PS
0.36
Overvalued PS
37.77
Undervalued PS
-25.63

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

please list me the top moving penny stocks
Intellectia · 65 candidates
Price: $0.10 - $5.00Volume: >= 0Price Change Pct: >= $0.00Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceAboveMA20Week Price Change Pct: >= $0.00Monthly Average Dollar Volume: >= 0
Ticker
Name
Market Cap$
top bottom
EHGO logo
EHGO
Eshallgo Inc
8.21M
GETY logo
GETY
Getty Images Holdings Inc
481.80M
TNON logo
TNON
Tenon Medical Inc
7.19M
SKYQ logo
SKYQ
Sky Quarry Inc
9.11M
CDT logo
CDT
CDT Equity Inc
7.29M
AZTR logo
AZTR
Azitra Inc
3.72M
predict most bullish ticker this month
Intellectia · 114 candidates
Rsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Month Rise Prob: >= 65One Month Predict Return: >= 10.0%
Ticker
Name
Market Cap$
top bottom
SPKL logo
SPKL
Spark I Acquisition Corp
98.18M
APXT logo
APXT
Apex Treasury Corp
458.22M
AMST logo
AMST
Amesite Inc
8.37M
CZFS logo
CZFS
Citizens Financial Services Inc
278.29M
JNJ logo
JNJ
Johnson & Johnson
571.52B
CRBU logo
CRBU
Caribou Biosciences Inc
184.58M
penny stocks to increase price this week
Intellectia · 11 candidates
Price: $0.20 - $5.00Moving Average Relationship: PriceAboveMA20One Week Rise Prob: >= 60One Week Predict Return: >= 5.0%
Ticker
Name
Market Cap$
top bottom
PSEC logo
PSEC
Prospect Capital Corp
1.37B
MTEK logo
MTEK
Maris Tech Ltd
14.13M
PRTS logo
PRTS
Carparts.Com Inc
44.40M
NSPR logo
NSPR
InspireMD Inc
77.12M
CHSN logo
CHSN
Chanson International Holding
86.92M
BRLS logo
BRLS
Borealis Foods Inc
40.14M
predict most bullish ticker next 3 months
Intellectia · 19 candidates
Analyst Consensus: Strong Buy, Moderate BuyMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Month Rise Prob: >= 65One Month Predict Return: >= 15.0%
Ticker
Name
Market Cap$
top bottom
GPCR logo
GPCR
Structure Therapeutics Inc
4.66B
ANDE logo
ANDE
Andersons Inc
2.19B
NCLH logo
NCLH
Norwegian Cruise Line Holdings Ltd
10.81B
ROG logo
ROG
Rogers Corp
1.98B
TNON logo
TNON
Tenon Medical Inc
8.89M
NI logo
NI
NiSource Inc
21.93B
predict most bullish ticker next 6 months
Intellectia · 3 candidates
Analyst Consensus: Strong Buy, Moderate BuyTarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Month Rise Prob: >= 75One Month Predict Return: >= 15.0%
Ticker
Name
Market Cap$
top bottom
ROG logo
ROG
Rogers Corp
1.98B
TNON logo
TNON
Tenon Medical Inc
8.89M
WALD logo
WALD
Waldencast PLC
224.36M

Whales Holding TNON

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Tenon Medical Inc (TNON) stock price today?

The current price of TNON is 0.2923 USD — it has decreased -10.43

What is Tenon Medical Inc (TNON)'s business?

Tenon Medical, Inc. is a medical device company. The Company has developed the Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Its trademarks include Catamaran, PiSIF, CAT PiSIF, ETAD, CAT SIJ Fusion System, SImmetry, MAINSAIL, SImmetry+, Catamaran Transfixation Fusion Device, Catamaran Transfixation Fusion System, and others. The Catamaran SI Joint Fusion System offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant.

What is the price predicton of TNON Stock?

Wall Street analysts forecast TNON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNON is2.75 USD with a low forecast of 2.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Tenon Medical Inc (TNON)'s revenue for the last quarter?

Tenon Medical Inc revenue for the last quarter amounts to 1.38M USD, increased 89.94

What is Tenon Medical Inc (TNON)'s earnings per share (EPS) for the last quarter?

Tenon Medical Inc. EPS for the last quarter amounts to -0.31 USD, decreased -69.31

How many employees does Tenon Medical Inc (TNON). have?

Tenon Medical Inc (TNON) has 26 emplpoyees as of July 05 2026.

What is Tenon Medical Inc (TNON) market cap?

Today TNON has the market capitalization of 5.66M USD.